Developed by China National Biotech Group, in collaboration with the Beijing Institute of Biological Products and the Chinese State Pharmaceutical, it is one of the vaccines already being tested in humans in Phase 3
November 10, 2020 Share on FacebookShare Share on TwitterTweet Share on WhatsAppShare
Developed by the CNBG (China National Biotech Group), in collaboration with the BIBP (Beijing Institute of Biological Products) and the Chinese state pharmaceutical company Sinopharm, BBIBP-CorV is one of 10 vaccines already being tested in humans in Phase 3 (REUTERS)
Faced with the global health crisis, several projects around the world are competing to find a vaccine against COVID-19, in a race of unprecedented speed, with gigantic financial interests. How many? The World Health Organization (WHO) reported at the beginning of this month of 47 vaccine projects in the world that are subject to clinical trials in humans. Ten are in Phase three, the most advanced, which involves tens of thousands of volunteers to test its effectiveness.
Among its manufacturers, the alliance between the American pharmaceutical company Pfizer and the German biotechnology company BioNTech stands out, which this Monday announced that its vaccine has an efficacy of 90%, according to the first results of that stage. Also included are the projects of the American pharmaceutical company Moderna, several Chinese state laboratories, the University of Oxford together with AstraZeneca and the Russian authorities and its research institute Gamaleïa.
In August this year it was announced that Liu Jingzhen, the president of the state-owned company China National Biotec Group, part of the pharmaceutical company Sinopharm , assured that the coronavirus vaccine in which the group works will be ready “probably in December” at a price of less than 1,000 yuan ($ 144). Later, the businessman told a press conference that the company could have the capacity to produce more than 1 billion doses in 2021.
China's Ministry of Science and Technology reported in late October that more than 60,000 volunteers received one of the four Chinese vaccine candidates against COVID19 “without presenting significant adverse effects.” In this framework, the laboratory Sinopharm reported that in his essay, carried out by the Institute of Biological Products in Beijing, they found “safety and tolerance” at their doses in all age groups, as well as “immunogenicity”. The researchers published the study data in the scientific journal The Lancet and stated that the objective was to “evaluate the safety and tolerability” of the inactivated BBIBP-CorV vaccine in patients 60 years of age or older.
In August this year it was announced that Liu Jingzhen, the president of the state-owned company China National Biotec Group, part of the pharmaceutical company Sinopharm, assured that the coronavirus vaccine in which the group works will be ready “probably in December” (REUTERS)
Developed by the CNBG ( China National Biotech Group ), in collaboration with the BIBP ( Beijing Institute of Biological Products) and the Chinese state pharmaceutical company Sinopharm , BBIBP-CorV is one of 10 vaccines already being tested in humans in Phase 3 . The BIBP is a prequalified institute by the WHO (World Health Organization), it is the main manufacturer of vaccines in China and the only Institute that has the regulatory approval of Biosafety Level 3 for the manufacture of vaccines based on virus culture .
” It is an inactivated virus vaccine , such as that for hepatitis A, polio and rabies, that is, vaccines that are absolutely safe from that point of view because they do not contain elements of live virus ,” he said in dialogue with this medium the Argentine infectologist Pedro Cahn, director of Fundación Huiuda and member of the Advisory Committee of President Alberto Fernández in the fight against the new coronavirus.
For his part, the infectologist Eduardo López maintained that the Sinopharm vaccine is based on dead virus. “They are viruses that grow in Vero cells , which belong to a cell lineage used in cell cultures (the Vero lineage was isolated from the epithelial cells of the kidney of an African green monkey). And after having a certain viral load, the vaccine is inactivated through chemical methods and then prepared for application. This platform has already been successfully tested in the Hepatitis A vaccine, and for Polio ”, recalled the specialist.
Reliance on homegrown vaccines is key to China's public health diplomacy in the face of accusations by the United States and other countries that reporting delays allowed the virus to spread from China (EFE / EPA / YFC / Archive)
China is among the countries leading the global race for a COVID-19 vaccine, with four treatments in the final phases of clinical trials. Health authorities have said that a vaccine will be available in China from November or December.
Under an emergency vaccine program that began in July, tens of thousands of volunteers have received experimental vaccines, raising questions about the risks of administering unproven treatments to the public.
Under the program, China offers three experimental injections developed by a unit of the state pharmaceutical giant China National Pharmaceutical Group and Sinovac Biotech, which is listed on the US stock exchange. A fourth vaccine being developed by CanSino Biologics was approved for use by the Chinese military in June.
Reliance on homegrown vaccines is key to China's public health diplomacy in the face of accusations by the United States and other countries that reporting delays allowed the virus to spread from China, becoming a pandemic spreading. it has claimed more than 1 million lives.
China recently joined Covax, a global vaccine initiative co-led by the World Health Organization, Gavi, the Vaccine Alliance, and the Coalition for Epidemic Preparedness and Innovations. By joining the coalition, rejected by the United States, China became the largest economy to participate.
I KEEP READING: